TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT04191278

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Varenicline
Description: All participants will receive a standard 12-week course of varenicline tartrate. Participants will receive 0.5 mg tablets per oral (PO) once daily for days 1-3, 0.5 mg tablets PO twice daily for days 4-7, and 1 mg tablets PO twice daily for days 8-84

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Varenicline
Description: All participants will receive a standard 12-week course of varenicline tartrate. Participants will receive 0.5 mg tablets per oral (PO) once daily for days 1-3, 0.5 mg tablets PO twice daily for days 4-7, and 1 mg tablets PO twice daily for days 8-84

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Varenicline
Description: All participants will receive a standard 12-week course of varenicline tartrate. Participants will receive 0.5 mg tablets per oral (PO) once daily for days 1-3, 0.5 mg tablets PO twice daily for days 4-7, and 1 mg tablets PO twice daily for days 8-84
Study: NCT05527470

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Intensity-modulated radiation therapy (IMRT)
Description: IMRT is given as 2.0-2.3 Gy per fraction with five daily fractions per week for 6-7 weeks, Cumulative doses were \> 66 Gy to the primary tumor and \> 50 Gy to the bilateral cervical lymph nodes and potential sites of local infiltration.

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Intensity-modulated radiation therapy (IMRT)
Description: IMRT is given as 2.0-2.3 Gy per fraction with five daily fractions per week for 6-7 weeks, Cumulative doses were \> 66 Gy to the primary tumor and \> 50 Gy to the bilateral cervical lymph nodes and potential sites of local infiltration.
Study: NCT04191278

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Mobile phone application
Description: Participants randomized to 2 of the 3 study groups will receive a mobile phone application designed to improve adherence to medication. The app has a number of functions, including: a) reminders to take medication; b) information about coping strategies for dealing with side effects and withdrawal symptoms; c) provision of a personalized graphical display of treatment progress (e.g., adherence, side effects); d) camera-based verification of having taken medication.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Mobile phone application
Description: Participants randomized to 2 of the 3 study groups will receive a mobile phone application designed to improve adherence to medication. The app has a number of functions, including: a) reminders to take medication; b) information about coping strategies for dealing with side effects and withdrawal symptoms; c) provision of a personalized graphical display of treatment progress (e.g., adherence, side effects); d) camera-based verification of having taken medication.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Contingency management
Description: Participants randomized to 1 of the 3 study groups will receive monetary reinforcement contingent upon verified medication adherence behaviors. Participants in the other 2 groups will be yoked to a participant in the CM group so that they also have a chance of earning monetary reinforcers, though not contingent upon their own behaviors.
Study: NCT05527470

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cisplatin
Description: Concurrent chemotherapy: Patients received 100mg/m2 cisplatin intravenously on day 1 to 3, three cycles were administered at intervals of 3 weeks.
Study: NCT04871087

Intervention type: DEVICE
Group type: OTHER
Intervention: Green Light
Description: The Allay Lamp is a consumer product currently available and widely used in the US. It emits low intensity (1-10lux)narrow band (20nm) green light (peak wavelength 520nm) that is marketed as non-irritating to users. In that context, it is not a medical device and does not require a 510(k). However, we believe that light likely also has benefits for sleep. To better understand its effects,we are planning to conduct the proposed study. In that context, the Allay Lamp would be considered an investigational medical device because it has not been cleared or approved by FDA for the intended purpose of treating sleep. No FDA submission should be necessary for this study using 21 C.F.R. 812.3, because the Allay Lamp is a non-significant risk (NSR) device:~It is not an implant It is not intended for use in supporting or sustaining human life The Allay Lamp provides a very low risk light-based therapy. The light provides no more risk than any other table lamp available on the market today.
Study: NCT04525274

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: normal saline
Description: At the end of surgery, patient will be shifted to Trendelenburg position and intraperitoneal instillation of 40 ml bupivacaine 0.25% + 5 ml normal saline will be done guided by the camera and sprayed uniformly into the peritoneal cavity by the surgeon.~The patient will be maintained in Trendelenburg position for 5-10 minutes after drug instillation and the abdomen will be deflated by passive exsufflation using gentle abdominal pressure.
Study: NCT06138847

Intervention type: DIAGNOSTIC_TEST
Intervention: electroencephalogram
Description: Polygraphic derivations generally include an ECG channel, which is standard on EEG recordings, plus an optional EMG channel. Subsequently, the signal was recorded at 512 Hz and inspected using the standard bipolar and referential montages
Study: NCT05605327

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: EUS-guided gastroenterostomy
Description: EUS-guided gastroenterostomy using the Hot-Axios and the WEST approach.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Laparoscopic gastroenterostomy
Description: Laparoscopic gastroenterostomy
Study: NCT06195280

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Magnetic resonance imaging, 3DT1 sequence
Description: The patient will have an exploration pelvic Magnetic Resonance Imaging lasting approximately 15 to 20 minutes, without systematic injection of contrast product.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Laparoscopy
Description: After Magnetic Resonance Imaging, the patient will benefit from a laparoscopy under general anesthesia lasting an average of one hour.
Study: NCT04525274

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: dexmedetomidine
Description: At the end of surgery, patient will be shifted to Trendelenburg position and intraperitoneal instillation of the study drug(40 ml bupivacaine 0.25% + 1 µg/kg dexmedetomidine diluted in 5 ml normal saline) will be done guided by the camera and sprayed uniformly into the peritoneal cavity by the surgeon.~The patient will be maintained in Trendelenburg position for 5-10 minutes after drug instillation and the abdomen will be deflated by passive exsufflation using gentle abdominal pressure.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ketamine
Description: At the end of surgery, patient will be shifted to Trendelenburg position and intraperitoneal instillation of the study drug(40 ml bupivacaine 0.25% + 0.5 mg/kg ketamine diluted in 5 ml normal saline) will be done guided by the camera and sprayed uniformly into the peritoneal cavity by the surgeon.~The patient will be maintained in Trendelenburg position for 5-10 minutes after drug instillation and the abdomen will be deflated by passive exsufflation using gentle abdominal pressure.
Study: NCT06073964

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Trauma Resilience & Understanding Self-help Therapy
Description: A self-help psychosocial therapeutic intervention requiring one to undergo a basic training in its community-based utilization.
Study: NCT03084952

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 18-Methoxycoronaridine
Description: Drug under evaluation for leishmaniasis treatment

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 18-Methoxycoronaridine
Description: Drug under evaluation for leishmaniasis treatment

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 18-Methoxycoronaridine
Description: Drug under evaluation for leishmaniasis treatment
Study: NCT05117125

Intervention type: DIAGNOSTIC_TEST
Intervention: Interleukin-26
Description: Evaluation of the specificity and sensitivity of IL-26 as diagnostic biomarker for VAP.

Intervention type: DIAGNOSTIC_TEST
Intervention: Interleukin-26
Description: Evaluation of the specificity and sensitivity of IL-26 as diagnostic biomarker for VAP.

Intervention type: DIAGNOSTIC_TEST
Intervention: Interleukin-26
Description: Evaluation of the specificity and sensitivity of IL-26 as diagnostic biomarker for VAP.

Intervention type: DIAGNOSTIC_TEST
Intervention: Microbiome
Description: Evaluation of the specificity and sensitivity of the lung microbiome as prognostic biomarker for VAP.
Study: NCT06499259

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Mandala coloring
Description: Mandala Pack and Application: The mandala pack is a pack consisting of 7 different patterns suitable for adults and 12 pencils. Mandala patterns will be photocopied by the researcher. Packages will be given to the mothers about mandala coloring and their questions will be answered. The choice of the color of the paint to be used in mandala coloring will be entirely up to the mother. No guidance will be given in this regard.
Study: NCT05878938

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NNC0365-3769 (Mim8) PPX
Description: Participants will receive Mim8 PPX once-weekly dosing (QW), once every two weeks dosing (Q2W), or once-monthly dosing s.c. injection using a prefilled fixed dose DV3407-C1 pen-injector for 26 weeks.
Study: NCT06416839

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: VR exercise
Description: Participation in high intensity interval training delivered on a virtual reality headset over six-week period. Participants may exercise with others in the multiplayer mode and use any feature of the application.
Study: NCT05379322

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Anti-TNF
Description: Upon analysis of the sample, patients that are falling into specific phenotypes (diffuse myeloid or pauci-cellular phenotypes) will be assigned to receive anti-TNF as biologic DMARD medications.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Anti-TNF
Description: Upon analysis of the sample, patients that are falling into specific phenotypes (diffuse myeloid or pauci-cellular phenotypes) will be assigned to receive anti-TNF as biologic DMARD medications.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JAK inhibitor
Description: Upon analysis of the sample, patients that are falling into specific phenotypes (lymphoid- myeloid or pauci-cellular phenotypes) will be assigned to receive JAK inhibitors as biologic DMARD medications.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JAK inhibitor
Description: Upon analysis of the sample, patients that are falling into specific phenotypes (lymphoid- myeloid or pauci-cellular phenotypes) will be assigned to receive JAK inhibitors as biologic DMARD medications.
Study: NCT05694078

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Hand Therapy Splinting Protocol
Description: Relative motion splinting protocol
Study: NCT05407298

Intervention type: OTHER
Intervention: Non applicable
Description: Non Applicable

Intervention type: OTHER
Intervention: Non applicable
Description: Non Applicable
Study: NCT05117125

Intervention type: DIAGNOSTIC_TEST
Intervention: Microbiome
Description: Evaluation of the specificity and sensitivity of the lung microbiome as prognostic biomarker for VAP.

Intervention type: DIAGNOSTIC_TEST
Intervention: Microbiome
Description: Evaluation of the specificity and sensitivity of the lung microbiome as prognostic biomarker for VAP.

Intervention type: DIAGNOSTIC_TEST
Intervention: Bacterial transcriptome
Description: Evaluation of the specificity and sensitivity of the bacterial transcriptome as prognostic biomarker for treatment failure of VAP.

Intervention type: DIAGNOSTIC_TEST
Intervention: Proteome
Description: Evaluation of the specificity and sensitivity of the proteome in mini-BAL as biomarker for VAP.

Intervention type: DIAGNOSTIC_TEST
Intervention: Proteome
Description: Evaluation of the specificity and sensitivity of the proteome in mini-BAL as biomarker for VAP.

Intervention type: DIAGNOSTIC_TEST
Intervention: Proteome
Description: Evaluation of the specificity and sensitivity of the proteome in mini-BAL as biomarker for VAP.
Study: NCT06084286

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Dual-targeting CLDN18.2 and PD-L1 CAR-T cells
Description: The trial consists of a traditional '3 + 3' pattern dose-escalation phase and a dose-expansion phase.
Study: NCT04787042

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ST-067
Description: ST-067 is an engineered variant of human interleukin-18.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ST-067
Description: ST-067 is an engineered variant of human interleukin-18.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ST-067
Description: ST-067 is an engineered variant of human interleukin-18.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ST-067
Description: ST-067 is an engineered variant of human interleukin-18.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Obinutuzumab 25 MG/1 ML Intravenous Solution [GAZYVA]
Description: Obinutuzumab is a humanized anti-CD20 monoclonal antibody of the IgG1 subclass. It recognizes a specific epitope of the CD20 molecule found on B-cells.
Study: NCT05587036

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo oral tablet, twice daily, two-weeks
Study: NCT05909436

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GLS-012
Description: In the dose escalation stage of GLS-012 monotherapy, RP2D will be determined. All subjects will receive GLS-012 intravenously Q3W.~In the expansion stage of GLS-012 monotherapy, subjects will receive up to 17 doses of GLS-012 at the RP2D administered Q3W.~In the dose escalation stage of GLS-012 combination with GLS-010, RP2D of GLS-012 in combination with a fixed-dose GLS-010 will be determined. All subjects will receive GLS-012 and GLS-010 intravenously Q3W.~In the expansion stage of GLS-012 combination with GLS-010, subjects will receive up to 35 doses of GLS-012 at the RP2D and GLS-010 at a fixed dose administered Q3W.
Study: NCT06156475

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Proprioception exercises
Description: Patients trained for proprioception exercises.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Proprioception exercises with Electromyographic Biofeedback
Description: Patients trained for Proprioception exercises with Electromyographic Biofeedback

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Wand Exercise
Description: Patients were educated with wand exercises.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Wand Exercise
Description: Patients were educated with wand exercises.
Study: NCT04787042

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: pembrolizumab
Description: Pembrolizumab is a potent humanized immunoglobulin G4 monoclonal antibody.
Study: NCT05306145

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: High freqnence Irreversible electroporation
Description: High freqnence Irreversible electroporation will be performed via the perineum with the guidance of ultrasound under general anaesthesia to the patient with benign prostatic hyperplasia

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Trans Urethral Resection Prostate
Description: Trans urethral resection prostate will be performed under general anaesthesia to the patient with benign prostatic
Study: NCT05570318

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Polyethylene Glycols
Description: To be taken orally on a daily basis throughout the study period (6 weeks) in an adjusted dose.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Polyethylene Glycols
Description: To be taken orally on a daily basis throughout the study period (6 weeks) in an adjusted dose.
Study: NCT04927000

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tofacitinib
Description: in tofacitinib treatment group，we added tofacitinib 5mg/BID in the basic treatment in all subjects.
Study: NCT05570318

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Low volume trans anal irrigation
Description: To be administered rectally on a daily basis throughout the study period (6 weeks) along with an adjusted dose of polyethylene glycols
Study: NCT06124313

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Vaginal Probiotic
Description: This product contains:~Probiotic Blend - 5 Strains Lactobacillus acidophilus Lactobacillus rhamnosus Lactobacillus gasseri Lactobacillus acidophilus (NCFM) Lactobacillus casei
Study: NCT05672615

Intervention type: OTHER
Intervention: Questionnaires
Description: Participants will be given the Zung Self-Rating Anxiety Scale and Zung Self-Rating Depression Scale to complete prior to each induction intravesical treatment and prior to 3-month follow-up appointments.

Intervention type: OTHER
Intervention: Questionnaires
Description: Participants will be given the Zung Self-Rating Anxiety Scale and Zung Self-Rating Depression Scale to complete prior to each induction intravesical treatment and prior to 3-month follow-up appointments.

Intervention type: OTHER
Intervention: Daily Mood Diaries
Description: Participants will be given daily mood diaries to complete during their 6-week induction intravesical treatment, 3-week maintenance treatment course, and between 3-month follow-up appointments.

Intervention type: OTHER
Intervention: Daily Mood Diaries
Description: Participants will be given daily mood diaries to complete during their 6-week induction intravesical treatment, 3-week maintenance treatment course, and between 3-month follow-up appointments.

Intervention type: OTHER
Intervention: Urine Specimen Collection
Description: Urine collections from patients will occur prior to each induction intravesical treatment and at 3-month follow-up cystoscopy appointments. An at home urine collection may occur 6 hours post intravesical treatment.

Intervention type: OTHER
Intervention: Urine Specimen Collection
Description: Urine collections from patients will occur prior to each induction intravesical treatment and at 3-month follow-up cystoscopy appointments. An at home urine collection may occur 6 hours post intravesical treatment.

Intervention type: OTHER
Intervention: Research Blood Draw
Description: Blood collections will occur prior to first intravesical treatment, prior to fourth intravesical treatment, and each 3-month cystoscopy as indicated by the participant's treatment course.

Intervention type: OTHER
Intervention: Research Blood Draw
Description: Blood collections will occur prior to first intravesical treatment, prior to fourth intravesical treatment, and each 3-month cystoscopy as indicated by the participant's treatment course.

Intervention type: OTHER
Intervention: Utilize excess tissue from a standard of care procedure
Description: Participants may indicate permission to provide excess tissue from a clinically indicated procedure for research purposes.

Intervention type: OTHER
Intervention: Utilize excess tissue from a standard of care procedure
Description: Participants may indicate permission to provide excess tissue from a clinically indicated procedure for research purposes.
Study: NCT06566703

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: All Nations Snuff Out Smokeless
Description: All Nations Snuff Out Smokeless is a culturally tailored smokeless tobacco cessation program that incorporates group-based and individual counseling.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: All Nations Snuff Out Smokeless
Description: All Nations Snuff Out Smokeless is a culturally tailored smokeless tobacco cessation program that incorporates group-based and individual counseling.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Healthy Living
Description: Healthy Living is an educational program that provides information about diet, exercise, stress, and general health. It uses group-based and individual discussion, along with educational materials.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Healthy Living
Description: Healthy Living is an educational program that provides information about diet, exercise, stress, and general health. It uses group-based and individual discussion, along with educational materials.
Study: NCT06541964

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Parent-Provide Distraction
Description: The children will be asked riddles by their parents for 5 seconds before and during the blood collection procedure.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Windmill Toy Blowing
Description: The children will blow on the windmill toy for 5 seconds before and during the blood collection procedure.
Study: NCT06348420

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: anti-reflux mucosal valvuloplasty (ARMV)
Description: During the ARMV procedure, a segment of the mucosa at the esophagogastric junction (EGJ) is released and reconstructed to form a mucosal flap. Cautery markings are made on 3/4-4/5 of the mucosa along the lesser curvature, approximately 2 cm below the dentate line. After submucosal injection of saline with indigocarmine, the premarked mucosa is dissected from the caudal to cranial side using an endoscopic submucosal dissection technique. The cranial edge of the released mucosa is left in place, and the semi-free mucosa naturally curls to form a double-layer flap. Metal clips are then used to anchor the free edge of the mucosa to the exposed submucosa/smooth muscle to prevent flattening of the mucosal flap. Any visible bleeding on the exposed submucosa is coagulated using electric forceps.
Study: NCT05216211

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bupivacaine Hydrochloride
Description: 1 ml / kg, % 0.25 bupivacaine
Study: NCT06541964

Intervention type: OTHER
Group type: OTHER
Intervention: Control
Description: No intervention will make on the children.
Study: NCT06125327

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SC1011
Description: Patients receive the dose of SC1011 tablets orally twice daily (b.i.d) for 52 weeks.
Study: NCT03084952

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 18-Methoxycoronaridine
Description: Drug under evaluation for leishmaniasis treatment

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 18-Methoxycoronaridine
Description: Drug under evaluation for leishmaniasis treatment
Study: NCT06125327

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo comparator
Description: Patients receive the dose of placebo orally twice daily (b.i.d) for 52 weeks.
Study: NCT03084952

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 18-Methoxycoronaridine
Description: Drug under evaluation for leishmaniasis treatment

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Glucantime
Description: Leishmaniasis standard drug in Brazil